Risk Factors and Primary Prevention Trials for Type 1 Diabetes
Open Access
- 1 January 2013
- journal article
- review article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 9 (7), 666-679
- https://doi.org/10.7150/ijbs.6610
Abstract
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease resulting in the designated immune destruction of insulin producing β-cells, usually diagnosed in youth, and associated with important psychological, familial, and social disorders. Once diagnosed, patients need lifelong insulin treatment and will experience multiple disease-associated complications. There is no cure for T1DM currently. The last decade has witnessed great progress in elucidating the causes and treatment of the disease based on numerous researches both in rodent models of spontaneous diabetes and in humans. This article summarises our current understanding of the pathogenesis of T1DM, the roles of the immune system, genes, environment and other factors in the continuing and rapid increase in T1DM incidence at younger ages in humans. In addition, we discuss the strategies for primary and secondary prevention trials of T1DM. The purpose of this review is to provide an overview of this disorder's pathogenesis, risk factors that cause the disease, as well as to bring forward an ideal approach to prevent and cure the disorder.Keywords
This publication has 102 references indexed in Scilit:
- Mycobacterium avium subsp. paratuberculosis as a trigger of type-1 diabetes: destination Sardinia, or beyond?Gut Pathogens, 2010
- The genetics and epigenetics of autoimmune diseasesJournal of Autoimmunity, 2009
- Regulation of Lymphoid Tyrosine Phosphatase Activity: Inhibition of the Catalytic Domain by the Proximal InterdomainBiochemistry, 2009
- C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes MellitusJAMA, 2009
- Several loci in the HLA class III region are associated with T1D risk after adjusting for DRB1‐DQB1Diabetes, Obesity and Metabolism, 2009
- Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety studyClinical and Experimental Immunology, 2008
- PD-1 deficiency reveals various tissue-specific autoimmunity by H-2band dose-dependent requirement of H-2g7for diabetes in NOD miceProceedings of the National Academy of Sciences of the United States of America, 2008
- Change in post‐translational modifications of histone H3, heat‐shock protein‐27 and MAP kinase p38 expression by curcumin in streptozotocin‐induced type I diabetic nephropathyBritish Journal of Pharmacology, 2008
- Humoral Immune Responses of Type 1 Diabetes Patients to Mycobacterium avium subsp. paratuberculosis Lend Support to the Infectious Trigger HypothesisClinical and Vaccine Immunology, 2008
- The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetesProceedings of the National Academy of Sciences of the United States of America, 2007